...
首页> 外文期刊>Journal of Clinical Microbiology >Investigation of Staphylococcus aureus Isolates Identified as Erythromycin Intermediate by the Vitek-1 System: Comparison with Results Obtained with the Vitek-2 and Phoenix Systems
【24h】

Investigation of Staphylococcus aureus Isolates Identified as Erythromycin Intermediate by the Vitek-1 System: Comparison with Results Obtained with the Vitek-2 and Phoenix Systems

机译:Vitek-1系统鉴定为红霉素中间体的金黄色葡萄球菌菌株的调查:与Vitek-2和Phoenix系统获得的结果比较

获取原文
           

摘要

We identified 69 Staphylococcus aureus isolates that were erythromycin intermediate as reported by the Vitek-1 system using the GPS-105 card. Of the 57 strains that were available for further testing, all were erythromycin resistant by broth microdilution and the Phoenix system, while the Vitek-2 system identified 55 of 57 strains (96%) as erythromycin resistant. The majority of isolates (54 of 57 [95%]) exhibited the inducible MLS (macrolide-lincosamide-streptogramin family) phenotype, as shown by the double-disk test. We recommend that all S. aureus strains determined as erythromycin intermediate by the Vitek-1 system be interpreted as resistant to erythromycin.
机译:根据Vitek-1系统使用GPS-105卡报告的结果,我们确定了69株金黄色葡萄球菌分离物为红霉素中间体。在可用于进一步测试的57个菌株中,全部通过肉汤微量稀释和Phoenix系统对红霉素具有抗性,而Vitek-2系统则在57个菌株中有55个(96%)对红霉素具有抗性。如双盘试验所示,大多数分离株(57个中的54个[95%])表现出可诱导的MLS(大环内酯-林可酰胺-链霉菌素家族)表型。我们建议所有 S。 Vitek-1系统确定为红霉素中间体的金黄色葡萄球菌菌株对红霉素具有抗性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号